Vertex (VRTX) Pops Higher, Enters Two New HCV Treatment Collaborations
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Up)Join SI Premium – FREE
Vertex Pharmaceuticals (Nasdaq: VRTX) shares are popping higher on the session following two news updates from the company on hepatitis C virus treatment development.
First, Vertex announced that it entered into a non-exclusive agreement with GlaxoSmithKline (NYSE: GSK) to conduct a Phase 2 proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135 and GSK’s NS5A inhibitor GSK2336805. Vertex and GSK plan to initiate the study in early 2013, pending discussions with regulatory authorities.
For more from the release, click here.
Also, Vertex said it entered into a non-exclusive collaboration with Janssen Pharmaceuticals, Inc. -- o f Johnson & Johnson (NYSE: JNJ) -- to conduct a Phase 2 proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135 and Janssen’s protease inhibitor simeprevir (TMC435). As part of the collaboration, Janssen will conduct a drug-drug interaction study with VX-135 and simeprevir to support the planned initiation of a Phase 2 proof-of-concept study in early 2013, pending discussions with regulatory authorities.
click here for the full release.
Shares are up over 7 percent on the session Thursday.
First, Vertex announced that it entered into a non-exclusive agreement with GlaxoSmithKline (NYSE: GSK) to conduct a Phase 2 proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135 and GSK’s NS5A inhibitor GSK2336805. Vertex and GSK plan to initiate the study in early 2013, pending discussions with regulatory authorities.
For more from the release, click here.
Also, Vertex said it entered into a non-exclusive collaboration with Janssen Pharmaceuticals, Inc. -- o f Johnson & Johnson (NYSE: JNJ) -- to conduct a Phase 2 proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing Vertex’s nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135 and Janssen’s protease inhibitor simeprevir (TMC435). As part of the collaboration, Janssen will conduct a drug-drug interaction study with VX-135 and simeprevir to support the planned initiation of a Phase 2 proof-of-concept study in early 2013, pending discussions with regulatory authorities.
click here for the full release.
Shares are up over 7 percent on the session Thursday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex Pharma (VRTX) Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
- Crown Castle (CCI) Issues Statement on "Ted Miller's Latest Attempt to Disrupt the Company's Momentum"
- Asbury Automotive Group (ABG) Announces Retirement of Chief Legal Officer
Create E-mail Alert Related Categories
Corporate News, FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
